GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Redx Pharma PLC (LSE:REDX) » Definitions » Net Cash per Share

Redx Pharma (LSE:REDX) Net Cash per Share : £-0.01 (As of Sep. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Redx Pharma Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Redx Pharma's Net Cash per Share for the quarter that ended in Sep. 2023 was £-0.01.

The historical rank and industry rank for Redx Pharma's Net Cash per Share or its related term are showing as below:

During the past 12 years, the highest Price-to-Net-Cash Ratio of Redx Pharma was 85.50. The lowest was 4.04. And the median was 8.07.

LSE:REDX's Price-to-Net-Cash is not ranked *
in the Biotechnology industry.
Industry Median: 4
* Ranked among companies with meaningful Price-to-Net-Cash only.

Redx Pharma Net Cash per Share Historical Data

The historical data trend for Redx Pharma's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redx Pharma Net Cash per Share Chart

Redx Pharma Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.04 -0.02 0.01 0.07 -0.01

Redx Pharma Semi-Annual Data
Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 -0.01 0.07 0.02 -0.01

Competitive Comparison of Redx Pharma's Net Cash per Share

For the Biotechnology subindustry, Redx Pharma's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Redx Pharma's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Redx Pharma's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Redx Pharma's Price-to-Net-Cash falls into.



Redx Pharma Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Redx Pharma's Net Cash per Share for the fiscal year that ended in Sep. 2023 is calculated as

Net Cash per Share (A: Sep. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(18.092-22.281-0)/334.911
=-0.01

Redx Pharma's Net Cash per Share for the quarter that ended in Sep. 2023 is calculated as

Net Cash per Share (Q: Sep. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(18.092-22.281-0)/334.911
=-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Redx Pharma  (LSE:REDX) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Redx Pharma Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Redx Pharma's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Redx Pharma (LSE:REDX) Business Description

Traded in Other Exchanges
N/A
Address
Block 33, Mereside, Alderley Park, Macclesfield, GBR, SK10 4TG
Redx Pharma PLC is a United Kingdom-based biotechnology company focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases. Its product pipeline under development includes Porcupine Inhibitor, ROCK2 Selective Inhibitor, GI-targeted ROCK inhibitor, Pan-RAF Inhibitor, and others. The firm operates geographically in UK and Ireland. Revenue is generated from; Scientific programmes and research collaboration, Research collaboration and Research and preclinical development services. Redx is a clinical-stage biotechnology company focused on the discovery & development of novel, small-molecule, targeted medicines for the treatment of cancer and fibrotic disease and the emerging area of cancer-associated fibrosis.

Redx Pharma (LSE:REDX) Headlines

No Headlines